Transpharmation Logo
  • Contact Us

Models & Assays

Drug Discrimination (Operant Platform)

All drugs of abuse, as well as certain non-abused drug classes, will produce an internal state that the rat can be trained to discriminate from a neutral stimulus such as saline injection. Drug discrimination procedures typically rely on a two-lever operant procedure. NCE’s may be tested for (a) their ability to either substitute (generalise) to a known drug cue (i.e suggestive of a similar interoceptive state) or (b) their ability to antagonise a known drug cue (i.e suggestive of an ability to block the interoceptive state of a known drug). Alternatively rats may be trained with an NCE to see if it can support a discrimination opening up opportunities to identify which known drugs may generalise. Transpharmation has experience in each of these areas.

Validation Data: Cross generalisation between a nicotine and diazepam cue
Nicotine cue
Diazepam cue

Separate groups of rats were trained to discriminate either nicotine (0.3 mg/kg) from saline (Nicotine), or Diazepam (2 mg/kg) from saline (DZP). As expected Nicotine trained rats showed a dose related generalisation to the nicotine lever, and DZP trained rats showed a dose related generalisation to the diazepam lever. However diazepam administered to Nicotine group, and nicotine administered to DZP group produced only at best a very weak (~25%) generalisation, thus showing the specificity of each cue type.

Company

  • Our Team
  • Publications
  • News
  • Careers
  • Animal Welfare
  • Privacy Policy
  • Accessibility Policy
  • Cookies Policy

Services

  • Abuse Liability / Substance Use Disorders
  • Alzheimer's Disease
  • Bioanalytical Studies
  • CNS Drug Disposition
  • Cognitive Assessment
  • Depression/Anxiety
  • Dermatology
  • EEG
  • Epilepsy
  • Essential Tremor
  • Imaging
  • Inflammatory Pain
  • Inflammation
  • Medical Cannabis
  • Metabolic Disorders
  • Migraine
  • Molecular Biomarkers
  • Multiple Sclerosis
  • Neuropathic Pain
  • Operant Platform
  • Osteoarthritis
  • Parkinson's Disease
  • PK/PD Studies
  • PK-Bridge
  • Psychedelics
  • PXB Mouse Studies
  • Safety Studies
  • Schizophrenia
  • Veterinary Research
North America
1-548-538-2371
Europe
+44 (0)130 440 3165
Contact us

© 2025 Transpharmation™. All Rights Reserved.
Sitemap
LinkedIn account
Youtube account